EVOK
Price:
$3.87
Market Cap:
$3.17M
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2013-09-25
Stock Exchange
NASDAQ
Ticker
EVOK
According to Evoke Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 0.03. This represents a change of -100.48% compared to the average of -6.29 of the last 4 quarters.
The mean historical PE Ratio of Evoke Pharma, Inc. over the last ten years is -33.49. The current 0.03 PE Ratio has changed -108.96% with respect to the historical average. Over the past ten years (40 quarters), EVOK's PE Ratio was at its highest in in the June 2024 quarter at -1.52. The PE Ratio was at its lowest in in the December 2017 quarter at -337.96.
Average
-33.49
Median
-27.89
Minimum
-65.33
Maximum
-5.41
Discovering the peaks and valleys of Evoke Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 97.66%
Maximum Annual PE Ratio = -5.41
Minimum Annual Increase = -60.47%
Minimum Annual PE Ratio = -65.33
Year | PE Ratio | Change |
---|---|---|
2023 | -5.41 | -56.36% |
2022 | -12.39 | -47.37% |
2021 | -23.53 | -60.47% |
2020 | -59.54 | -2.56% |
2019 | -61.10 | -6.48% |
2018 | -65.33 | 97.66% |
2017 | -33.05 | 56.88% |
2016 | -21.07 | -0.61% |
2015 | -21.20 | -34.28% |
2014 | -32.25 | -56.80% |
The current PE Ratio of Evoke Pharma, Inc. (EVOK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-13.78
5-year avg
-32.39
10-year avg
-33.49
Evoke Pharma, Inc.’s PE Ratio is greater than Petros Pharmaceuticals, Inc. (-0.19), greater than Cumberland Pharmaceuticals Inc. (-1.76), greater than Agile Therapeutics, Inc. (-0.65), greater than PainReform Ltd. (-0.05), greater than Aquestive Therapeutics, Inc. (-14.78), greater than Adamis Pharmaceuticals Corporation (-0.47), greater than Guardion Health Sciences, Inc. (-2.89), greater than AcelRx Pharmaceuticals, Inc. (-1.83), less than Eagle Pharmaceuticals, Inc. (5.10), greater than Regencell Bioscience Holdings Limited (-18.48), less than Procaps Group S.A. (4.69), greater than Incannex Healthcare Limited (-1.34), less than Journey Medical Corporation (111.00), greater than Jupiter Wellness, Inc. (-3.87), greater than Avadel Pharmaceuticals plc (-13.12), greater than Biofrontera Inc. (-0.42), greater than Shuttle Pharmaceuticals Holdings, Inc. (-0.48), greater than Akanda Corp. (-0.11), greater than China Pharma Holdings, Inc. (-0.65),
Company | PE Ratio | Market cap |
---|---|---|
-0.19 | $3.27M | |
-1.76 | $18.25M | |
-0.65 | $10.43M | |
-0.05 | $1.81M | |
-14.78 | $380.63M | |
-0.47 | $7.25M | |
-2.89 | $17.02M | |
-1.83 | $14.58M | |
5.10 | $55.19M | |
-18.48 | $87.06M | |
4.69 | $218.91M | |
-1.34 | $29.29M | |
111.00 | $97.00M | |
-3.87 | $49.33M | |
-13.12 | $1.39B | |
-0.42 | $6.15M | |
-0.48 | $3.42M | |
-0.11 | $2.11M | |
-0.65 | $3.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Evoke Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Evoke Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Evoke Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Evoke Pharma, Inc. (EVOK)?
What is the highest PE Ratio for Evoke Pharma, Inc. (EVOK)?
What is the 3-year average PE Ratio for Evoke Pharma, Inc. (EVOK)?
What is the 5-year average PE Ratio for Evoke Pharma, Inc. (EVOK)?
How does the current PE Ratio for Evoke Pharma, Inc. (EVOK) compare to its historical average?